In daily clinical practice, in-stent restenosis (ISR) is defined
|
|
- Shauna Caldwell
- 5 years ago
- Views:
Transcription
1 Impact of In-Stent Minimal Lumen Area at 9 Months Poststent Implantation on 3-Year Target Lesion Revascularization Free Survival A Serial Intravascular Ultrasound Analysis From the TAXUS IV, V, and VI Trials Hiroshi Doi, MD, PhD; Akiko Maehara, MD; Gary S. Mintz, MD; Neil J. Weissman, MD; Alan Yu, MS; Hong Wang, MS; Lazar Mandinov, MD; Jeffrey J. Popma, MD; Stephen G. Ellis, MD; Eberhard Grube, MD; Keith D. Dawkins, MD; and Gregg W. Stone, MD Background Intravascular ultrasound (IVUS) is used to assess intermediate lesions in native coronary arteries; minimum lumen area (MLA) 4.0 mm 2 is accepted as a cutoff for a significant stenosis. We evaluated the IVUS in-stent MLA at 9-month follow-up that best predicted subsequent target lesion revascularization (TLR) free survival in patients from the TAXUS IV, V, and VI studies. Methods and Results In the combined TAXUS IV, V, and VI randomized trials, 9-month IVUS was available in 635 patients (331 treated with paclitaxel-eluting stents [PES] and 304 treated with bare-metal stents [BMS]) who did not require TLR in the first 9 months postintervention and who were followed for 3 years. The in-stent MLA that best predicted 3-year TLR-free survival was determined. At 9-months follow-up, IVUS-measured in-stent MLA was mm 2 in the PES group and mm 2 in the BMS group. Between 9 months and 3 years, TLR was required in 4.9% of patients who were treated with PES and 6.7% of patients who were treated with BMS. Multivariate analysis identified MLA at 9 months as a significant predictor of late TLR (hazard ratio, 0.63 [ ]; P 0.02). The ability of MLA to predict late TLR was further assessed using receiver operating characteristic analysis. MLA was found to be an acceptable discriminator for both PES (c ) and BMS (c ). Finally, the optimal thresholds of MLA that best predicted subsequent TLR-free survival were determined to be 4.2 mm 2 for PES and 4.0 mm 2 for BMS. Conclusion In the combined IVUS analysis of TAXUS IV, V, and VI, patients who did not require TLR within the first 9 months had a high subsequent TLR-free survival rate whether treated with PES or BMS. MLA measured by IVUS at 9 months predicted subsequent TLR with a cutoff similar to intermediate, de novo lesions in native coronary arteries. (Circ Cardiovasc Intervent. 2008;1: ) Key Words: intravascular ultrasound restenosis stents In daily clinical practice, in-stent restenosis (ISR) is defined angiographically, and patients with 50% angiographic diameter stenosis typically undergo a repeat intervention. Although coronary angiography has been accepted as the gold standard for the quantification of coronary artery disease, including ISR lesions, several reports have shown its limitation in the assessment of intermediate lesions. 1 3 Intravascular ultrasound (IVUS) and invasive physiological analyses such as Doppler FloWire (Volcano Corporation, Rancho Cordova, Calif) and coronary pressure wire were developed, in part, to assess intermediate lesions. 4 Among these techniques, the IVUS-measured minimum lumen area (MLA), the Doppler FloWire measured coronary flow reserve, and the pressure wire measured fractional flow reserve (FFR) have been used to identify a significant de novo stenosis. 5 7 However, the application of these techniques has not been reported for intermediate ISR lesions. Editorial see p 90 Clinical Perspective see p 118 To address this issue, we used data from the major paclitaxel-eluting stent (PES) versus bare-metal stent (BMS) Received April 6, 2008; accepted August 13, From the Cardiovascular Research Foundation, New York, NY (H.D., A.M., G.S.M., G.W.S.); Columbia University Medical Center, New York, NY (H.D., A.M., G.S.M., G.W.S.); Washington Hospital Center, Washington, DC (N.W.W.); Boston Scientific Corporation, Natick, Mass (A.Y., H.W., L.M., K.D.D.); St Elizabeth Medical Center, Boston, Mass (J.J.P); Cleveland Clinic, Cleveland, Ohio (S.G.E.); and Heart Center Siegburg, Siegburg, Germany (E.G.). Correspondence to Gary S. Mintz, MD, 611 Pennsylvania Ave, SE #386, Washington, DC gsm18439@aol.com 2008 American Heart Association, Inc. Circ Cardiovasc Intervent is available at DOI: /CIRCINTERVENTIONS
2 112 Circ Cardiovasc Intervent October 2008 randomized TAXUS IV, V, and VI trials These trials included substudies of patients who underwent 9-month follow-up IVUS imaging and 3-year clinical follow-up. We hypothesized that 9-month IVUS can predict 3-year target lesion revascularization (TLR) free survival in patients receiving PES and BMS. Methods Patient Population and Protocol TAXUS IV, TAXUS V, and TAXUS VI were prospective, double-blind, BMS-controlled trials in which patients with a single de novo native coronary artery lesion were randomly assigned to treatment with a PES or an otherwise identical BMS (Boston Scientific, Natick, Mass) The TAXUS IV and V studies used the TAXUS slow-release formulation (commercially available), whereas TAXUS VI used the TAXUS moderaterelease formulation (not commercially available). IVUS substudy data from these trials were analyzed at a single core laboratory (Medlantic Research Institute, Washington Hospital Center, Washington, DC) as described previously. 11 Of the 2918 patients enrolled in the 3 trials, the first 956 patients enrolled at prespecified IVUS substudy sites underwent serial volumetric IVUS analysis and were included in the IVUS cohort, including 268 from TAXUS IV, 509 from TAXUS V, and 179 from TAXUS VI. In the IVUS cohort, 635 patients (331 PES and 304 BMS) did not require TLR in the first 9 months post stent implantation, including the day of the 9-month angiography/ivus follow-up and were followed for 3 years. TLR was defined as any ischemia-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. All TLR throughout follow-up (up to and including the 3-year follow-up) were adjudicated by the Clinical Events Committee (Harvard Clinical Research Institute, Boston, Mass). If the lesion diameter stenosis was 70%, no additional clinical evidence of ischemia was needed. If the lesion diameter stenosis was 50% but 70%, one of the following pieces of evidence was needed: (1) positive functional study corresponding to the area served by the target lesion, (2) ischemic ECG changes at rest in a distribution consistent with the target vessel, or (3) ischemic symptoms referable to the target lesion. If the lesion diameter stenosis was 50%, a markedly positive functional study or ECG changes corresponding to the area served by the target vessel was needed. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agreed to the manuscript as written. Angiography Analysis Two or more angiographic projections of the stenosis after intracoronary nitroglycerin were acquired with repetition of identical angiographic projections of the lesion at the time of follow-up angiography. With the contrast-filled catheter as the calibration source, quantitative angiographic analysis was performed using a validated automated edge-detection algorithm (MEDIS Medical Imaging System, Maastricht, The Netherlands) by a technician who was unaware of the clinical or IVUS findings and who was blinded to the treatment arm. IVUS Protocol and Analysis Clinical sites were selected based on their IVUS experience and volume. Volumetric IVUS was performed immediately after stent implantation and at 9-month follow-up in patients at the IVUS substudy sites of each trial until the prespecified enrollment numbers in each trial were obtained. IVUS imaging was performed after intracoronary administration of 0.1 to 0.2 mg of nitroglycerin using motorized transducer pullback (0.5 mm/s) and contemporary, commercial scanners. Images were continuously recorded throughout the stent, including 5-mm segments distal and proximal to the stent. Images were recorded onto s-vhs videotape, compact discs, or magneto-optical discs for offline analysis at a single, independent core laboratory by a technician who was unaware of treatment assignment or patient clinical outcomes. With the use of computerized planimetry (TapeMeasure, Indec Systems, Mountain View, Calif.), stent and lumen borders were manually traced, and stent, lumen, and intimal hyperplasia (stent lumen) areas were calculated every 1 mm within the stented segment. Volumes were calculated using the Simpson rule. Percentage of intimal hyperplasia (%IH) was defined as intimal hyperplasia volume divided by stent volume. MLA was defined as the smallest lumen area within the length of the stent. Minimum stent area was defined as the smallest stent area within the length of the stent. Statistical Analysis Categorical variables were summarized as frequencies and percentages and were compared between groups using 2 tests or Fisher exact tests, as appropriate. Continuous variables were presented as mean SD and compared between groups using 2-tailed, unpaired t tests;if parameters were not normally distributed per Kolmogorov- Smirnov test, then the Wilcoxon 2-sample test was used. Multivariate analysis was used to determine predictors of late TLR (between 9 months and 3 years). All covariates were modeled univariately for each outcome and multivariately using a stepwise procedure in the Cox regression model. Baseline patient and lesion characteristics and 9-month IVUS variables were included. Statistical significance was set at P For each outcome, predictors were listed in ascending order of probability value. Coefficients with probability values 0.05 were not listed. Receiver operating characteristic (ROC) analysis was used to measure the ability of MLA and %IH at 9-months follow-up to discriminate between those subjects who experienced TLR within the subsequent follow-up (between 9 months and 3 years) compared with those who did not. The ROC curves plot the probability of detecting true signals (sensitivity) against false signals (1 specificity) over an entire range of possible cut points. Acceptable discrimination is considered if the c statistic is 0.7 but 0.8; excellent and outstanding discrimination are considered for c statistics 0.8 but 0.9, and 0.9, respectively. To determine the optimal IVUS cutoff value for each treatment group to best predict late (3-year) TLR, the cross point of sensitivity and specificity curves was used. The Kaplan-Meier product-limit method and log-rank tests were used to assess time-to-event end points between treatment groups. Differences were considered to be statistically significant when the probability value was Results This study consisted of 635 patients with IVUS data (331 PES and 304 BMS) who did not require TLR in the first 9 months post stent implantation, who were not staged for intervention after the 9-month coronary angiography and IVUS, and who were subsequently followed for 3 years. Between the 9-month and 3-year follow-up visits, TLR was necessary in 16 patients who were treated with PES (4.9%) and 20 patients who were treated with BMS (6.7%). The time from 9-month follow-up IVUS to the late TLR event was days in the PES group and days in the BMS group. TLR-free survival curves are shown in Figure 1 and were not different between the 2 groups. Only 1 patient in each group developed stent thrombosis between 9 months and 3 years. Patients and Lesion Characteristics Baseline clinical and lesion characteristics of late-tlr patients were similar to those of TLR-free patients in the PES
3 Doi et al Nine-Month In-Stent MLA and 3-Year TLR %; P ), and a smaller external elastic membrane area ( versus mm 2 ; P ) as compared with patients treated with PES who did not undergo TLR during the follow-up period (Table 3). Figure 1. Kaplan-Meyer TLR-free survival curves in 635 patients (331 treated with PES and 304 treated with BMS) who did not require TLR in the first 9 months post stent implantation and who were followed for 3 years. At 3 years, TLR-free survival rates in the PES- and BMS-treated groups were 95.1% and 93.3%, respectively. and BMS groups (Tables 1 and 2). In addition, baseline clinical and lesion characteristics were similar between the PES and BMS groups (Tables 1 and 2). Thus, baseline clinical characteristics, including incidence of diabetes mellitus and lesion severity, did not affect the magnitude of late TLR. IVUS Findings at 9 Months in the PES Group At 9 months, patients treated with PES who required revascularization within 3 years had a smaller minimum stent area ( versus mm 2 ; P ), a smaller MLA ( versus mm 2 ; P ), a greater in-stent volume obstruction (%IH volume, % versus Table 1. Clinical and Angiographic Findings in the PES Group Total (N 331) IVUS Findings at 9 Months in the BMS Group At 9 months, patients treated with BMS who required revascularization within 3 years had a smaller MLA ( versus mm 2 ; P ) and a greater in-stent volume obstruction (%IH volume, % versus %; P ) as compared with patients treated with BMS who did not undergo TLR during the follow-up period. However, there was only a trend toward a smaller minimum stent area ( versus mm 2 ; P ) and smaller external elastic membrane area ( versus mm 2 ; P ) between the 2 groups (Table 4) in patients with late TLR versus TLR-free patients. IVUS-Measured MLA and %IH Predicted Late TLR Multivariate analysis identified MLA (hazard ratio, 0.63 [ ]; P 0.02) and %IH volume (hazard ratio, 1.07 [ ]; P ) as the only predictors of late TLR. We performed ROC analysis of the MLA and %IH to ascertain and compare their ability to predict patients who would receive late TLR versus those with no late TLR. The ROC analysis of MLA showed that the c statistics in the TAXUS and BMS groups were and , respectively (Figure 2). In addition, ROC analysis of %IH volume Late TLR (N 16) No Late TLR (N 315) P value Age, years Female, n (%) 84 (25) 4 (25) 80 (25) 1.00 Diabetes, n (%) 86 (26) 2 (13) 84 (27) 0.26 Hypertension, n (%) 225 (68) 11 (69) 214 (68) 1.00 Hyperlipidemia, n (%) 232 (70) 10 (67) 222 (71) 0.77 Smoking, n (%) 74 (22) 3 (19) 71 (23) 1.00 Prior MI, n (%) 104 (31) 6 (38) 98 (31) 0.59 Unstable AP, n (%) 108 (33) 2 (13) 106 (34) 0.10 Ejection fraction, % Vessel LAD, n (%) 139 (42) 8 (50) 131 (42) 0.61 LCX, n (%) 96 (29) 5 (31) 91 (29) 0.79 RCA, n (%) 94 (29) 3 (19) 91 (29) 057 Baseline angiographic findings Type C lesion, n (%) 117 (35) 5 (31) 112 (36) 0.80 Lesion length, mm RVD, mm MLD, mm DS, % MI indicates myocardial infarction; AP, angina pectoris; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; RVD, reference vessel diameter; MLD, minimum lumen diameter; DS, diameter stenosis.
4 114 Circ Cardiovasc Intervent October 2008 Table 2. Clinical and Angiographic Findings in the BMS Group Total (N 304) Late TLR (N 20) No Late TLR (N 284) P value Age, years Female, n (%) 87 (29) 6 (30) 81 (29) 1.00 Diabetes, n (%) 72 (24) 5 (25) 67 (24) 1.00 Hypertension, n (%) 198 (65) 15 (75) 183 (64) 0.47 Hyperlipidemia, n (%) 208 (68) 10 (50) 198 (70) 0.08 Smoking, n (%) 50 (16) 4 (20) 46 (16) 0.75 Prior MI, n (%) 89 (29) 4 (20) 85 (30) 0.45 Unstable AP, n (%) 94 (31) 4 (20) 90 (32) 0.33 Ejection fraction, % Vessel LAD, n (%) 125 (41) 12 (63) 113 (40) LCX, n (%) 79 (26) 4 (21) 75 (27) 0.79 RCA, n (%) 97 (32) 3 (16) 94 (33) 0.13 Baseline angiographic findings Type C lesion, n (%) 103 (34) 4 (20) 99 (35) 0.32 Lesion length, mm RVD, mm MLD, mm DS, % MI indicates myocardial infarction; AP, angina pectoris; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; RVD, reference vessel diameter; MLD, minimum lumen diameter; DS, diameter stenosis. showed that the c statistics in TAXUS and BMS groups were and , respectively (Figure 3). Using the cross points of the sensitivity and specificity curves for 9-month MLA and %IH as discriminators for 3-year TLR probability, the best cutoff values were 4.2 mm 2 (PES) and 4.0 mm 2 (BMS) for MLA (Figure 4) and 24.5% (PES) and 23.9% (BMS) for %IH volume. The rate of late TLR in PES-treated patients with a 9-month MLA 4.0 mm 2 was 2.9% as compared with 11.6% in patients with an MLA 4.0 mm 2 (P ). Although 9-month MLA 4.0 mm 2 demonstrated a high predictive value for TLR-free survival of 97.2%, MLA 4.0 mm 2 had only an 11.4% predictive value Table 3. IVUS and Angiographic Findings at 9-Month Follow-Up in PES-Treated Patients of late TLR. In the BMS cohort, the late-tlr rate in patients with 9-month MLA 4.0 mm 2 was 3.5% as compared with 11.1% in patients with MLA 4.0 mm 2 (P ). Similar to PES, the predictive value of an MLA 4.0 mm 2 for TLR-free survival in BMS patients was 96.6%, whereas the predictive value of MLA 4.0 mm 2 for late TLR was only 10.9%. Discussion The major findings of this study were as follows: (1) in the combined IVUS analysis of TAXUS IV, V, and VI, patients who did not require TLR within the first 9 months Total Late-TLR No Late-TLR P value IVUS findings (N 331) (N 16) (N 315) MSA, mm (4.6, 6.3, 8.1) (4.5, 5.2, 6.1) (4.8, 6.2, 7.8) 0.10 MLA, mm (4.0, 5.5, 7.2) (1.7, 3.0, 5.2) (4.2, 5.5, 7.2) IH volume, % (2.3, 8.9, 18.4) (10.7, 18.4, 40.5) (2.1, 8.5, 18.1) EEM area, mm (11.6, 15.0, 19.1) (10.1, 11.6, 13.7) (12.1, 15.2, 19.1) Angiographic findings (N 322) (N 14) (N 308) In-segment MLD, mm (1.8, 2.1, 2.4) (1.1, 1.4, 1.9) (1.8, 2.1, 2.4) In-segment DS, % (16.8, 23.0, 33.3) (35.1, 49.4, 58.3) (16.5, 22.9, 32.1) In-segment binary restenosis (%DS 50), % 5.3 (17/322) 50.0 (7/14) 3.3 (10/308) * P values are from Wilcoxon 2-sample tests for continuous data. Data are presented as mean SD (1st quartile, median, 3rd quartile). MSA indicates minimal stent area; IH, intimal hyperplasia; EEM, external elastic membrane; MLD, minimum lumen diameter; DS, diameter stenosis. *P value is from Fisher exact test.
5 Doi et al Nine-Month In-Stent MLA and 3-Year TLR 115 Table 4. IVUS and Angiographic Findings at 9-Month Follow-Up in BMS-Treated Patients Total Late TLR No Late TLR P value IVUS findings (N 304) (N 20) (N 284) MSA, mm (4.5, 6.1, 8.4) (3.6, 5.2, 6.7) (5.1, 6.6, 8.5) MLA, mm (2.9, 4.6, 6.3) (1.5, 2.2, 4.9) (3.1, 4.7, 6.4) IH volume, % (20.3, 29.4, 39.2) (32.3, 49.4, 60.8) (19.1, 28.4, 37.9) EEM area, mm (12.1, 15.1, 18.4) (10.5, 13.4, 14.9) (12.1, 15.3, 18.4) 0.07 Angiographic findings (N 290) (N 16) (N 274) In-segment MLD, mm (1.4, 1.8, 2.2) (0.8, 1.0, 1.4) (1.5, 1.9, 2.2) In-segment DS, % (24.6, 33.2, 45.1) (45.8, 60.6, 65.5) (24.0, 32.3, 42.5) In-segment binary restenosis (%DS 50), % 19.3 (56/290) 62.5 (10/16) 16.8 (46/274) * P values are from Wilcoxon 2-sample tests for continuous data. Data are presented as mean SD (1st quartile, median, 3rd quartile). MSA indicates minimal stent area; IH, intimal hyperplasia; EEM, external elastic membrane; MLD, minimum lumen diameter; DS, diameter stenosis. *P value is from Fisher exact test. had a very low 3-year TLR rate regardless of whether they were treated with PES (3-year TLR rate of 4.9%) or BMS (3-year TLR rate of 6.7%); and (2) in-stent MLA measured by IVUS at 9 months predicted TLR-free survival during subsequent follow-up in both PES- and BMS-treated groups, and the MLA cutoffs (4.2 and 4.0 mm 2, respectively) were virtually identical. In patients with an MLA 4.0 mm 2, late TLR rates in patients treated with PES or BMS were especially low (2.9% and 3.5%, respectively). Thus, just as IVUS is useful in assessing intermediate de novo lesions, IVUS is also useful in assessing intermediate ISR lesions; patients with intermediate ISR lesions (MLA 4.0 mm 2 ) can be treated medically with good long-term outcomes. Several studies have reported a strong correlation between anatomic data obtained from IVUS and physiological data obtained using coronary flow reserve, FFR, or radionuclide angiographic stress testing. Abizaid et al 5 studied 112 de novo lesions in 86 patients with both IVUS and coronary flow reserve; an IVUS lumen cross-sectional area of 4.0 mm 2 predicted a coronary flow reserve of 2.0 with a diagnostic accuracy of 89%. Nishioka et al 12 reported that an IVUS MLA 4.0 mm 2 correlated with abnormal stress myocardial single-photon emission computed tomography (sensitivity of 88% and specificity of 90%). Takagi et al 13 examined 51 lesions in 42 patients using both IVUS and pressure wire; although an MLA of 3.0 mm 2 best predicted an abnormal FFR, regression analysis of individual data points showed that an IVUS MLA of 4.0 mm 2 best correlated with an FFR of 0.75 to The use of IVUS to assess intermediate, native, de novo lesions has been validated clinically. Abizaid et al 14 studied 357 intermediate lesions in 300 patients in whom intervention was deferred based on IVUS findings; TLR was required in 6% of the patients at a mean follow-up of 13 months. Moreover, patients with an MLA 4.0 mm 2 by IVUS had only a 2.8% rate of TLR, although the TLR rate was higher in diabetics as compared with nondiabetics. There have been preliminary reports on the use of IVUS to assess intermediate ISR lesions. Nishioka et al 15 studied 150 intermediate ISR lesions in 142 patients. Repeat intervention was deferred if the MLA measured by IVUS was 3.5 mm 2 ; in these patients, the 2-year event-free survival rate was high (96.5%). Lee et al 16 evaluated the long-term clinical outcome of asymptomatic patients with moderate ISR after repeat intervention was deferred; during a mean follow-up of 26 months, TLR (3% and 2%, respectively) and major adverse cardiac event -free survival (87% and 85%, respectively) were similar to a group of patients without ISR. As in the study by Abizaid et al 14 of native artery lesions, the presence of diabetes mellitus Figure 2. ROC analysis of MLA at 9-month follow-up for predicting 3-year TLR. The areas under the curve in ROC analysis in the PESand BMS-treated groups were and , respectively.
6 116 Circ Cardiovasc Intervent October 2008 Figure 3. ROC analysis of the %IH at 9-month follow-up for predicting 3-year TLR. The areas under the curve in ROC analysis in the PES- and BMS-treated groups were and 0.803, respectively. influenced late events in ISR lesions. 16 However, because of the small number of patients who required 3-year TLR in the current study, we were unable to assess the impact of diabetes mellitus (or other risk factors) on long-term outcome. Intracoronary physiology has also been used to assess ISR lesions. Compared with reversible perfusion defects on myocardial scintigraphy, an FFR 0.75 predicted hemodynamically significant ISR with a sensitivity of 92%. Krüger et al 17 studied 42 intermediate ISR lesions. In 22 patients with an FFR 0.75, there were no adverse coronary events related to the stented lesion in the subsequent 6 months. Thus, similar to IVUS, the FFR threshold for a significant ISR lesion was similar to de novo lesions. Kimura et al 18 demonstrated that in-stent luminal diameter measured by quantitative angiography in patients treated with the Palmaz-Schatz stent improved from 1.95 to 2.09 mm between 6 months and 3 years postimplantation. In a subsequent report, Kimura et al 19 analyzed late clinical and angiographic outcomes after Palmaz-Schatz stent implantation. Among the 405 patients in this second study, quantitative angiographic analysis of 179 lesions in 173 patients showed a minimum lumen diameter of 2.62 mm postprocedure, 2.00 mm at 6 months, 2.19 mm at 3 years, and 1.85 mm beyond 4 years. These data indicated a triphasic BMS luminal response, characterized by early restenosis, intermediate-term neointima regression (from 6 months to 3 years), and late renarrowing (beyond 4 years). In support of intermediate-term neointima regression after BMS implantation, Kuroda et al 20 reported that intimal hyperplasia area measured by IVUS decreased from 3.0 mm 2 at 6 months to 2.2 mm 2 at 12 months. Also using IVUS, Hong et al 21 showed that there was intimal hyperplasia regression in most BMS-treated lesions (76%), with an overall mean decrease in intimal hyperplasia area from 2.6 mm 2 at 6 months to 2.3 mm 2 at 2 years. The longest available IVUS follow-up after PES implantation is also 2 years. In an IVUS substudy from TAXUS II, Aoki et al 22 showed that there was a modest increase in %IH in the PES group as compared with a decreased in %IH in the BMS group between 6 months and 2 years. In another long-term IVUS substudy from ASPECT (a study that used a nonpolymeric paclitaxel stent), Park et al 23 demonstrated a late catch-up of intimal hyperplasia growth from 6 to 18 months, especially in the high-dose group. These differences between PES and BMS led to the hypothesis that the 9-month MLA cutoff predicting late TLR would be larger in PES as compared with BMS because a larger MLA would be necessary to accommodate ongoing neointimal hyperplasia in PES-treated lesions. In fact, this was not the case; the MLA cutoffs were nearly identical. This finding, along with virtually identical event-free survival curves, also suggested that any late intimal hyperplasia would have little clinical consequence. Figure 4. Sensitivity and specificity curves for 9-month follow-up MLA predicting 3-year TLR.
7 Doi et al Nine-Month In-Stent MLA and 3-Year TLR 117 Study Limitations First, in this study, we evaluated only PES; however, the late intimal hyperplasia growth patterns in other drug-eluting stents might be similar to those in PES. Second, the results in this study are limited to vessel diameters, stent lengths, and lesion complexities in the TAXUS IV, V, and VI trials. Third, the TAXUS trials were not undertaken to evaluate the efficacy of IVUS for decision-making in intermediate ISR lesions. Since an MLA 4.0 mm 2 had low predictive value for late TLR, and given the lack of evidence that treatment of these lesions would benefit patients without objective evidence of ischemia, these findings should not be taken as a prescription to routinely treat patients with MLA 4.0 mm 2. Fourth, comparisons between groups are not powered and are used either for descriptive purpose or to show consistency with the predictive analysis, which is the major focus of this article. Finally, these results are based on IVUS analysis only and cannot be extrapolated to any angiographic data because of lack of correlation between angiographic and IVUS measures. Conclusions and Clinical Implications In the combined IVUS analysis of TAXUS IV, V, and VI, patients who did not require TLR within the first 9 months had a low subsequent (3-year) TLR rate whether treated with PES or BMS. In-stent MLA measured by IVUS at 9 months predicted subsequent 3-year TLR-free survival in both the PES and BMS groups, with cutoffs virtually identical to and event rates as low as in intermediate, de novo, native artery lesions. The low late-tlr rates in patients with MLA 4 mm 2 at 9 months brings uncertainty to the practice of intervening on moderate lesions at routine follow-up, even in the absence of symptoms mostly due to the oculostenotic reflex. Conversely, patients with intermediate ISR lesions (MLA 4.0 mm 2 ) can be treated medically with good long-term outcomes. Thus, IVUS may also be a useful modality for decision-making in intermediate ISR lesions. Disclosures Drs Mintz and Stone are consultants for Boston Scientific Corporation. Alan Yu, Hong Wang, and Drs Mandinov and Dawkins are employees of Boston Scientific Corporation. Dr Popma is a member of the Advisory Board and the Speaker s Bureau for Boston Scientific Corporation and has received research grants from Boston Scientific Corporation. References 1. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316: Tobis JM, Mallery J, Mahon D, Lehmann K, Zalesky P, Griffith J, Gessert J, Moriuchi M, McRae M, Dwyer ML. Intravascular ultrasound imaging of human coronary arteries in vivo. Analysis of tissue characterizations with comparison to in vitro histological specimens. Circulation. 1991;83: Hodgson JM, Reddy KG, Suneja R, Nair RN, Lesnefsky EJ, Sheehan HM. Intracoronary ultrasound imaging: correlation of plaque morphology with angiography, clinical syndrome and procedural results in patients undergoing coronary angioplasty. J Am Coll Cardiol. 1993;21: Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory. J Am Coll Cardiol. 2007;49: Abizaid A, Mintz GS, Pichard AD, Kent KM, Satler LF, Walsh CL, Popma JJ, Leon MB. Clinical, intravascular ultrasound, and quantitative angiographic determinants of the coronary flow reserve before and after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1998;82: Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, Segal J. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85: Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334: Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME. Clinical efficacy of polymer-based paclitaxeleluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drugeluting stents in contemporary clinical practice. Circulation. 2005; 112: Stone GW, Ellis SG, Cox DA, Hermiller J, O Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350: Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. Jama. 2005;294: Weissman NJ, Ellis SG, Grube E, Dawkins KD, Greenberg JD, Mann T, Cannon LA, Cambier PA, Fernandez S, Mintz GS, Mandinov L, Koglin J, Stone GW. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J. 2007;28: Nishioka T, Amanullah AM, Luo H, Berglund H, Kim CJ, Nagai T, Hakamata N, Katsushika S, Uehata A, Takase B, Isojima K, Berman DS, Siegel RJ. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. J Am Coll Cardiol. 1999;33: Takagi A, Tsurumi Y, Ishii Y, Suzuki K, Kawana M, Kasanuki H. Clinical potential of intravascular ultrasound for physiological assessment of coronary stenosis: relationship between quantitative ultrasound tomography and pressure-derived fractional flow reserve. Circulation. 1999;100: Abizaid AS, Mintz GS, Mehran R, Abizaid A, Lansky AJ, Pichard AD, Satler LF, Wu H, Pappas C, Kent KM, Leon MB. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. Circulation. 1999;100: Nishioka H, Shimada K, Fukuda D Long-term follow-up of intermediate in-stent restenosis lesions following deferral of re-intervention on the basis of intravascular ultrasound findings. Circulation. 2002;106.:II-587. Abstract Lee JH, Lee CW, Park SW, Hong MK, Kim JJ, Rhee KS, Park SJ. Long-term follow-up after deferring angioplasty in asymptomatic patients with moderate noncritical in-stent restenosis. Clin Cardiol. 2001;24: Krüger S, Koch KC, Kaumanns I, Merx MW, Hanrath P, Hoffmann R. Clinical significance of fractional flow reserve for evaluation of functional lesion severity in stent restenosis and native coronary arteries. Chest. 2005;128: Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, Sato Y, Hamasaki N, Nosaka H. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334: Kimura T, Abe K, Shizuta S, Odashiro K, Yoshida Y, Sakai K, Kaitani K, Inoue K, Nakagawa Y, Yokoi H, Iwabuchi M, Hamasaki N, Nosaka H, Nobuyoshi M. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002; 105:
8 118 Circ Cardiovasc Intervent October Kuroda N, Kobayashi Y, Nameki M, Kuriyama N, Kinoshita T, Okuno T, Yamamoto Y, Komiyama N, Masuda Y. Intimal hyperplasia regression from 6 to 12 months after stenting. Am J Cardiol. 2002;89: Hong MK, Lee CW, Kim YH, Lee BK, Kim MK, Yang TH, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Two-year follow-up intravascular ultrasound analysis after bare metal stent implantation in 120 lesions. Catheter Cardiovasc Interv. 2005;65: Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, Schiele F, Russell ME, Koglin J, Serruys PW. Persistent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation. 2005;112: Park DW, Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, Weissman NJ, Park SW, Park SJ. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late catch-up phenomenon from ASPECT Study. J Am Coll Cardiol. 2006;48: CLINICAL PERSPECTIVE In treating patients with complex coronary artery disease, physicians are often faced with deciding which lesions to treat and which lesions to leave alone. This can be especially difficult when a patient has had a prior intervention. Intravascular ultrasound (IVUS) can be used to assess de novo intermediate lesions in native coronary arteries; a minimum lumen area (MLA) 4.0 mm 2 is accepted as a cutoff for a significant stenosis. However, the use of IVUS to assess intermediate in-stent restenosis lesions has not been reported. In the current study, we used the IVUS substudy data from TAXUS IV, V, and VI to assess the 9-month IVUS in-stent MLA that best predicted subsequent target lesion revascularization (TLR) free survival. Nine-month IVUS data were available for 635 patients (331 treated with paclitaxel-eluting stents and 304 treated with bare-metal stents) who did not require TLR in the first 9 months postintervention and who were followed for a total of 3 years. Multivariate analysis identified the 9-month IVUS MLA as a significant predictor of late TLR. The MLA that best predicted subsequent TLR-free survival was 4.2 mm 2 for paclitaxel-eluting stents and 4.0 mm 2 for bare-metal stents. The late TLR rate of patients with a 9-month IVUS MLA 4.0 mm 2 was lower as compared with the late TLR rate in the setting of an MLA 4.0 mm 2 in both treatment groups (paclitaxel-eluting stents: late TLR,2.9%, versus no late TLR, 11.6% [P ]; bare-metal stents: 3.5% versus 11.1% [P 0.009]). Patients with intermediate in-stent restenosis lesions (MLA 4.0 mm 2 ) can be treated medically with good long-term outcomes. Thus, IVUS is a useful modality for decision-making in intermediate in-stent restenosis lesions similar to de novo lesions.
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationLate and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis
Late and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis Soo-Jin Kang, MD; Gary S. Mintz, MD; Duk-Woo Park, MD; Seung-Whan Lee, MD; Young-Hak Kim, MD; Cheol Whan Lee,
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationChronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 2, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2007.12.005 Chronic
More informationTwo-Year Follow-Up Intravascular Ultrasound Analysis After Bare Metal Stent Implantation in 120 Lesions
Catheterization and Cardiovascular Interventions 65:247 253 (2005) Two-Year Follow-Up Intravascular Ultrasound Analysis After Bare Metal Stent Implantation in 120 Lesions Myeong-Ki Hong, MD, PhD, Cheol
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationDrug-eluting stents (DES) reduce the rate of restenosis and
Original Articles Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation Intravascular Ultrasound Analysis Soo-Jin Kang, MD; Gary S. Mintz, MD; Duk-Woo Park, MD; Seung-Whan Lee, MD; Young-Hak
More informationAnatomy is Destiny, But Physiology is Here Today
Published on Journal of Invasive Cardiology (http://www.invasivecardiology.com) September, 2010 [1] Anatomy is Destiny, But Physiology is Here Today Thu, 9/9/10-10:54am 0 Comments Section: Commentary Issue
More informationIntravascular Ultrasound in the Drug-Eluting Stent Era
Journal of the American College of Cardiology Vol. 48, No. 3, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.04.068
More informationAngiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis
1630 JACC Vol. 32, No. 6 Angiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis SHUNJI KASAOKA, MD, JONATHAN M. TOBIS, MD, FACC, TATSURO AKIYAMA, MD,* BERNHARD REIMERS, MD,* CARLO
More informationCardiovascular Research Foundation and Columbia University Medical Center, New York.
Virtual Histology Intravascular Ultrasound Analysis of Non-culprit Attenuated Plaques Detected by Grayscale Intravascular Ultrasound in Patients with Acute Coronary Syndromes Xiaofan Wu, Akiko Maehara,
More informationFIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study
Journal of the American College of Cardiology Vol. 61, No. 9, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.012
More informationIntegrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
More informationIVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
More informationEvaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013
Evaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013 Disclosures Consultant- St Jude Medical Boston Scientific Speaker- Volcano Corporation Heart
More informationInterventional Cardiology
Interventional Cardiology Late Malapposition After Drug-Eluting Implantation An Intravascular Ultrasound Analysis With Long-Term Follow-Up Myeong-Ki Hong, MD, PhD; Gary S. Mintz, MD; Cheol Whan Lee, MD,
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationIVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation
IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More informationIntravascular Ultrasound Predictors for Edge Restenosis After Newer Generation Drug-Eluting Stent Implantation
Intravascular Ultrasound Predictors for Edge After Newer Generation Drug-Eluting Stent Implantation Soo-Jin Kang, MD, PhD a, Young-Rak Cho, MD a, Gyung-Min Park, MD a, Jung-Min Ahn, MD a, Won-Jang Kim,
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationPredictors for Functionally Significant In-Stent Restenosis
JACC: CARDIOVASCULAR IMAGING VOL. 6, NO. 11, 2013 ª 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcmg.2013.09.006 Predictors
More informationValidation of Minimal Luminal Area Measured by Intravascular Ultrasound for Assessment of Functionally Significant Coronary Stenosis
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 6, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.02.013 Validation
More informationNew Insight about FFR and IVUS MLA
New Insight about FFR and IVUS MLA Can IVUS MLA Predict FFR
More informationQuick guide. Core. precision guided therapy system
Quick guide Core precision guided therapy system The Philips Volcano imaging system should only be operated by trained personnel. The following information is presented for your convenience and is not
More informationIntravascular ultrasound-based analysis of factors affecting minimum lumen area in coronary artery intermediate lesions
Journal of Geriatric Cardiology (2016) 13: 169 174 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Intravascular ultrasound-based analysis of factors affecting minimum lumen area
More informationAlthough a feasible therapeutic alternative to bypass
Comprehensive Intravascular Ultrasound Assessment of Stent Area and Its Impact on Restenosis and Adverse Cardiac Events in 403 Patients With Unprotected Left Main Disease Soo-Jin Kang, MD, PhD; Jung-Min
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationAngiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions
244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary
More informationBetween Coronary Angiography and Fractional Flow Reserve
Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve Seung-Jung Park, MD., PhD. University of Ulsan, College of Medicine Asan Medical Center, Seoul, Korea Visual - Functional
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationFractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center
Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationFrequency and Characteristics of Incomplete Stent Apposition During and After Sirolimus-Eluting Stent Implantation
J Cardiol 2007 Aug; 50 2 : 111 118 Frequency and Characteristics of Incomplete Stent Apposition During and After Sirolimus-Eluting Stent Implantation Hiroki Yoshihiro Daisuke Tadashi Yota Naoko Nami Masakazu
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationFFR and IVUS Guided DES Implantation in Long Diffuse Lesions
FFR and IVUS Guided DES Implantation in Long Diffuse Lesions Can We Reach Optimal DES Expansion With Conventional Stent Delivery System in Long Diffuse Lesion? Seung-Jea Tahk, MD., PhD. Ajou University
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationThe Influence of Diabetes Mellitus on Acute and Late Clinical Outcomes Following Coronary Stent Implantation
584 JACC Vol. 32, No. 3 The Influence of Diabetes Mellitus on Acute and Late Clinical Outcomes Following Coronary Stent Implantation ALEXANDRE ABIZAID, MD, RAN KORNOWSKI, MD, GARY S. MINTZ, MD, FACC, MUN
More informationOne-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial
Tabriz University of Medical Sciences Original Article One-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial Samad Ghaffari MD, Mohammad Reza Hasanian MD, Leili Pourafkari
More informationRestenosis after implantation of sirolimus-eluting stent begins suddenly, shows short term progression, and stops suddenly
Journal of Cardiology (2011) 58, 26 31 a va i la b le at www.sciencedirect.com jo ur nal home page: www.elsevier.com/locate/jjcc Original article Restenosis after implantation of sirolimus-eluting stent
More informationPrimary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone
Journal of Cardiology (2008) 51, 18 24 Primary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone Hajime Fujimoto, Susumu Tao, Tomotaka Dohi, Sachiko Ito, Jun
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationIntegrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes. Gary S. Mintz, MD Cardiovascular Research Foundation
Integrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes Gary S. Mintz, MD Cardiovascular Research Foundation COURAGE Nuclear Substudy (n=314) Death/MI according the residual ischemia (SPECT)
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationJournal of the American College of Cardiology Vol. 39, No. 8, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01774-6
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013
840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1
More informationThe Site of Plaque Rupture in Native Coronary Arteries
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.067
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationGary S. Mintz,, MD. IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function
Gary S. Mintz,, MD IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function Important IVUS Observations: Remodeling Originally used (first by Glagov) ) to explain atherosclerosis
More informationFor Personal Use. Copyright HMP 2013
Case Report J INVASIVE CARDIOL 2013;25(2):E39-E41 A Case With Successful Retrograde Stent Delivery via AC Branch for Tortuous Right Coronary Artery Yoshiki Uehara, MD, PhD, Mitsuyuki Shimizu, MD, PhD,
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationΚλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE
Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE Conflict of interest None to declare While IVUS is the most used intravascular
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationCan IVUS Define Plaque Features that Impact Patient Care?
Can IVUS Define Plaque Features that Impact Patient Care? A Pichard L Satler, K Kent, R Waksman, W Suddath, N Bernardo, N Weissman, M Angelo, D Harrington, J Lindsay, J Panza. Washington Hospital Center
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationIntracoronary stents reduce restenosis compared with balloon
Treatment of In-Stent Restenosis With Excimer Laser Coronary Angioplasty Versus Rotational Atherectomy Comparative Mechanisms and Results Roxana Mehran, MD; George Dangas, MD, PhD; Gary S. Mintz, MD; Ron
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationIVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.
Left Main and Bifurcation Summit IVUS-Guided d Provisional i Stenting: ti Plaque or Carina Shift Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan College of Medicine Asan Medical Center,
More informationJournal of the American College of Cardiology Vol. 34, No. 1, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 1, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00151-5 Mechanisms
More informationFFR and intravascular imaging, which of which?
FFR and intravascular imaging, which of which? Ayman Khairy MD, PhD, FESC Associate professor of Cardiovascular Medicine Vice Director of Assiut University Hospitals Assiut, Egypt Diagnostic assessment
More informationas a Mechanism of Stent Failure
In-Stent t Neoatherosclerosis e osc e os s as a Mechanism of Stent Failure Soo-Jin Kang MD., PhD. University of Ulsan College of Medicine, Heart Institute Asan Medical Center, Seoul, Korea Disclosure I
More informationJournal of the American College of Cardiology Vol. 34, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00324-1 Final
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More informationDespite its benefit over balloon angioplasty in patients
Coronary Heart Disease Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries Jeffrey J. Popma, MD; Martin B. Leon, MD; Jeffrey W. Moses,
More informationPlaque Shift vs. Carina Shift Prevalence and Implication
TCTAP 2013 Fellowship Course Left Main and Bifurcation PCI: Bifurcation PCI Plaque Shift vs. Carina Shift Prevalence and Implication Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationJournal of the American College of Cardiology Vol. 57, No. 12, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.041
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 7, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 7, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.03.013 Optimal Intravascular
More informationShould we be using fractional flow reserve more routinely to select stable coronary patients for percutaneous coronary intervention?
REVIEW C URRENT OPINION Should we be using fractional flow reserve more routinely to select stable coronary patients for percutaneous coronary intervention? Seung-Jung Park and Jung-Min Ahn Purpose of
More informationFFR in Left Main Disease
FFR in Left Main Disease William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Why FFR instead of IVUS? Physiologic versus anatomic
More informationOutcomes With the Paclitaxel-Eluting Stent in Patients With Acute Coronary Syndromes Analysis From the TAXUS-IV Trial
Journal of the American College of Cardiology Vol. 45, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.10.074
More informationBasics of Angiographic Interpretation Analysis of Angiography
Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast
More informationINTRODUCTION. ORIGINAL ARTICLE DOI: /kjim
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.4.356 Usual Dose of Simvastatin Does Not Inhibit Plaque Progression and Lumen Loss at the Peri-Stent Reference Segments after Bare-Metal Stent Implantation: A
More informationPredictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease
Original Article Acta Cardiol Sin 2009;25:1 6 Coronary Artery Disease Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease Yung-Lung Chen,
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE A Comparison between the Instantaneous Wave-free Ratio and Resting Distal Coronary Artery Pressure/Aortic Pressure and the Fractional Flow Reserve: The Diagnostic Accuracy CanBeImprovedbytheUseofbothIndices
More informationCoronary Artery Disease
Coronary Artery Disease Fractional Flow Reserve Assessment of Left Main Stenosis in the Presence of Downstream Coronary Stenoses Andy S.C. Yong, MBBS, PhD*; David Daniels, MD*; Bernard De Bruyne, MD, PhD;
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationComplex PCI. Your partner in complex PCI: In-stent restenosis (ISR)
Comple PCI Your partner in comple PCI: Your partner in comple PCI: Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationDrug eluting stents (DES) have decreased
JACC: CARDIOVASCULAR IMAGING VOL. 5, NO. 11, 1 1 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jcmg.1.. BRIEF REPORT OCT-Verified
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationSo-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of Medicine, Korea
So-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of Medicine, Korea Anatomical vs Functional Significance? Coronary Angiogram Treadmill Test Tc-99m-MIBI SPECT MDCT Coronary Angiogram
More information